Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 34Lymphoma, Non-Hodgkin 30Leukemia, Myeloid, Acute 25Hodgkin Disease 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 11Lymphoma 10Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 6Neoplasms, Plasma Cell 5Recurrence 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Glioblastoma 3Warts 2Sezary Syndrome 2Neutropenia 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Hairy Cell 2Infections 2Immunologic Deficiency Syndromes 2

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Lomustine 25Cisplatin 25Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × plerixafor × Clear all
NCT01288573 2017-05-16

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Sanofi

Phase 1/2 Completed
46 enrolled
CNS

Brain Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡